The global conversation around obesity and type 2 diabetes management has shifted dramatically in recent years, largely due to the rise of GLP-1 receptor compounds. Among them, semaglutide has emerged as one of the most effective modern therapies, transforming how clinicians approach both blood sugar control and weight management. However, high costs and limited availability have meant that many patients, especially in price-sensitive countries, could not easily access this treatment.
That situation will now change as patent protections begin to expire in several markets starting March 20, 2026, opening the door to more affordable generic versions.
Understanding Semaglutide and How It Works
Semaglutide belongs to a class of medicines known as GLP-1 receptor compounds. These drugs mimic the action of a naturally occurring hormone called glucagon-like peptide-1, which is released in the gut after eating.
This hormone plays multiple roles in the body:
- It stimulates insulin release when blood sugar levels rise
- It reduces excess glucose production in the liver
- It slows the rate at which the stomach empties
- It acts on appetite centres in the brain to promote a feeling of fullness
Together, these effects help patients achieve better long-term glucose control while also reducing calorie intake. Unlike many older therapies, semaglutide addresses both diabetes and obesity simultaneously, the two conditions that frequently occur together and significantly raise cardiovascular risk.
What Patent Expiry Really Means
When a pharmaceutical patent expires, other manufacturers are legally allowed to produce medicines containing the same active ingredient. These are known as generic drugs. However, to say this with certainty, generic molecules need to undergo bioequivalence trials with the innovator/original molecule to see if one unit of the generic molecule is equivalent to one unit of the original molecule.
Generics are essentially identical to their branded counterparts in terms of dosage, safety, effectiveness and quality standards. Regulatory authorities require them to undergo strict evaluation before approval, ensuring patients receive the same therapeutic benefit at a lower cost.
Patent expiry therefore does not signal a change in the medicine itself. Rather, it marks the beginning of wider competition, which typically leads to price reductions and improved availability.
Why Greater Access Matters for Patients
Obesity and type 2 diabetes are rising rapidly across the world, driven by sedentary lifestyles, dietary changes and genetic predisposition. Both conditions increase the likelihood of heart disease, kidney failure and stroke, placing a heavy burden on families and healthcare systems.
For many patients, lifestyle modification alone is not sufficient. While balanced diets, exercise and behavioural therapy remain essential, some individuals require medical support to regulate appetite, improve metabolism and reduce cardiometabolic risk.
Until recently, semaglutide treatment was financially out of reach for a large section of patients. Monthly therapy costs often consumed a significant share of household income, especially where health insurance coverage is limited.
Lower-priced generics could allow:
- Earlier medical intervention
- Better long-term disease control
- Reduced risk of complications
- Fewer hospitalisations
- Improved quality of life
In public health terms, broader access may help shift treatment from crisis management to preventive care.
Special Considerations for Asian Populations
Emerging research suggests that many Asian populations develop metabolic complications at lower body mass index (BMI) levels than Western populations. A phenotype often described as “thin-fat” – where individuals appear lean but carry high visceral fat. This increases vulnerability to diabetes and heart disease even when BMI falls within traditional “normal” ranges.
Because semaglutide has shown particular effectiveness in reducing visceral fat, it could play an important preventive role in such populations. However, treatment eligibility criteria in many countries still rely heavily on BMI thresholds derived from Western data.
Public health authorities may therefore need to adapt guidelines to ensure that high-risk individuals are not excluded from potentially beneficial therapy.
